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Background: Intermediate outcomes are common and typically on the causal pathway to the final outcome. Some
examples include noncompliance, missing data, and truncation by death like pregnancy (e.g. when the trial
intervention is given to non-pregnant women and the final outcome is preeclampsia, defined only on pregnant
women). The intention-to-treat approach does not account properly for them, and more appropriate alternative
approaches like principal stratification are not yet widely known. The purposes of this study are to inform
researchers that the intention-to-treat approach unfortunately does not fit all problems we face in experimental
research, to introduce the principal stratification approach for dealing with intermediate outcomes, and to illustrate
its application to a trial of long term calcium supplementation in women at high risk of preeclampsia.
Methods: Principal stratification and related concepts are introduced. Two ways for estimating causal effects are
discussed and their application is illustrated using the calcium trial, where noncompliance and pregnancy are
considered as intermediate outcomes, and preeclampsia is the main final outcome.
Results: The limitations of traditional approaches and methods for dealing with intermediate outcomes are
demonstrated. The steps, assumptions and required calculations involved in the application of the principal
stratification approach are discussed in detail in the case of our calcium trial.
Conclusions: The intention-to-treat approach is a very sound one but unfortunately it does not fit all problems we
find in randomized clinical trials; this is particularly the case for intermediate outcomes, where alternative
approaches like principal stratification should be considered.
Keywords: Intermediate outcomes, Intention-to-treat approach, Principal stratification, Causal effectsBackground
The presence of intermediate outcomes (IO), both in
experimental and observational research, complicates the
assessment of causal effects between exposures and (final)
outcomes [1]. Methodological and statistical approaches
for dealing with this problem have been proposed for
quite a time [2-5], but many researchers are not yet famil-
iar with them. The purpose of this article is to present an
intuitive introduction to a framework for studying causal
effects when IOs are present, principal stratification (PS),
and a related statistical technique, instrumental variables
(IV). We illustrate concepts and methods using the World
Health Organization (WHO) randomized trial of calcium* Correspondence: seuca@who.int
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reproduction in any medium, provided the orsupplementation before pregnancy to reduce recurrent
preeclampsia [6].
Before describing the techniques we present a summary
of the calcium trial, and a few basic definitions that are
required to understand them. We expect that this paper
will help researchers conducting randomized clinical trials
(RCT) to become more familiar with these techniques,
and that their proper application will be further promoted.Methods
Summary description of the calcium supplementation
trial
Calcium supplementation has been shown to reduce se-
verity of preeclampsia, maternal morbidity and newborn
mortality when supplementation starts at around mid-
pregnancy, and particularly in women with low calcium
intake [6]. However, calcium supplementation in thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Difference between confounders and intermediate
outcomes.
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eclamptic processes, and it has been proposed that further
improvements in outcomes may be achieved by earlier
supplementation. Consequently, the WHO randomized
trial of calcium supplementation before pregnancy to
reduce recurrent preeclampsia [6] aims at assessing if cal-
cium supplementation before and in the first half of preg-
nancy reduces the incidence of recurrent preeclampsia
more effectively than supplementation starting at
20 weeks.
The trial will be conducted in maternities in South
Africa, Zimbabwe and Argentina. Participants in the trial
will be women who have had preeclampsia or eclampsia
in their most recent pregnancy and are planning to be-
come pregnant. The trial will randomize 1,410 subjects,
and it is expected that about 700 women (half) will get
pregnant, 350 in each trial group. The estimated duration
of the trial is four years over which 540 pregnant women
(270 in each trial group) are estimated to remain in the
sample and will be included in the final analysis. The
primary outcome of the trial will be incidence of
preeclampsia.
The study group will receive calcium supplementation
with 500 mg elemental calcium daily from enrolment
(before pregnancy) until 20 weeks’ gestation, and the
control group will receive placebo. All women will re-
ceive calcium supplementation (1.5 mg) unblinded from
20 weeks’ gestation until delivery. If pre-pregnancy
calcium supplementation is found to be effective, the
groundwork will have been done for research and then
implementation of food fortification programs. The pos-
sibility for calcium supplementation to affect the risk of
pregnancy is very low, but it cannot be ruled out. The
protocol has been approved by the institutional review
boards of the participating centres. All of the partici-
pants will provide written informed consent.
Some relevant definitions
In epidemiology, an IO (sometimes known as a mediating
variable) is ‘any factor that represents a step in the causal
chain between the exposure and disease [that] should not
be treated as an extraneous confounding factor, but
instead requires special treatment’ [7,8]. In causal terms,
the confounder is expected to cause the exposure, but the
exposure will cause the intermediate outcome [7]. See
Figure 1.
For example, in the WHO calcium supplementation
trial described above, compliance to treatment assigned
(calcium or placebo) is an intermediate outcome, not a
confounder, between assignment to calcium and pre-
eclampsia (or even pregnancy). As subjects in the cal-
cium trial will be randomly assigned to calcium we will
in general not have confounders as nothing can cause
randomization; this systematic tendency to avoid bias(from confounding) is one of the main reasons why
results from RCTs are more credible than those from
observational studies.
Also in this context, pregnancy is a (potential) inter-
mediate outcome, not a confounder, between treatment
assigned (or treatment received) and preeclampsia. If there
were theoretical and/or empirical evidence that indeed
calcium influences the risk of pregnancy, then pregnancy
would be an intermediate outcome; if the risk of preg-
nancy were independent of calcium intake, then preg-
nancy would not be an intermediate outcome. In this last
scenario, the subgroup of pregnant women in each of the
two trial arms would be a random sample, no selection
bias would be present and the effect of calcium supple-
mentation on preeclampsia could safely be conducted
comparing the corresponding subgroups of pregnant
women.
If the intermediate outcome also causes exposure,
then it is also a confounder. This is essentially possible
only in observational studies, as in experimental studies
it is usually possible to identify the direction of the
causal effect. For example, in an observational cohort
study considering the effect of exposure to tobacco and
alcohol on heart diseases, the two-way dependency be-
tween tobacco and alcohol makes each of them a con-
founder and also an intermediate outcome, with respect
to the outcome heart disease.
Other relevant related terms are endogenous variable
and instrumental variable, traditionally used in the context
of non-experimental studies. An endogenous explanatory
variable is an explanatory variable in a regression model
that is correlated with the error term, either because of an
omitted variable, measurement error, or the explanatory
variable is (also) determined by the dependent variable
(reverse causality) [7].
An IV is a variable not included in the regression
model, which is uncorrelated with the error term (that
is, uncorrelated with the dependent variable) and is
(partially) correlated with the endogenous explanatory
variable [7,9]. IVs have a long history within econometrics
but are not yet widely used in the health sciences [10,11].
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pose that in our calcium trial example we try to predict
pregnancy using treatment received (calcium/placebo)
as a predictor; then treatment received is in general an
endogenous explanatory variable because of the potential
selection bias that noncompliance (from being random-
ized to effectively taking calcium) might introduce. Those
who do receive calcium are in general not comparable to
those who do not, which means that we need other pre-
dictors to properly model the response variable pregnancy,
making treatment received an endogenous variable.
To illustrate the term IV in the context of RCTs, let us
follow up the previous example where treatment received
was an endogenous variable; in this scenario treatment
assigned is an IV because i) it does (potentially) effect
pregnancy only through effective calcium intake, and ii)
calcium intake is (positively) correlated to calcium assign-
ment. Then this treatment assigned IV is used to remove
or mitigate the endogeneity of treatment received as a
predictor for pregnancy; this is done using, for example,
two-stage least squares (TSLS) regression.
Random assignment to treatment is frequently used in
RCTs as an IV when we are interested in the causal effect
of treatment (effectively) received on the (final) outcome,
as it helps to obtain less biased causal effect estimations in
the presence of significant lack of treatment compliance
[9]. IV analyses are frequently conducted in observational
studies; in these cases it relies on finding an IV, which is
usually a naturally varying phenomenon, related to treat-
ment but not to outcome, except through the effect of
treatment itself, and then using this phenomenon as a
proxy for the confounded treatment variable. In doing so
the IV analysis of observational studies parallels the RCT
design [12].
An intuitive justification for finding and using IV is
that under certain conditions the association of interest
between exposure (treatment received) R and outcome
Y, Assoc RY, can be written as:
AssocTY ¼ AssocTR  AssocRY: ð1Þ
where T is the IV; solving for the association between R
and Y in (1) provides a better estimate of the relevant
parameter than the unadjusted (or crude) association,
when conditions i) and ii) above are met [11]. In the
above examples we can observe that IVs become the
new (proxy) exposures, while the original exposures are
recycled as IO.
Finally, trials can be classified as pragmatic trials or
explanatory trials. Pragmatic trials are those designed to
assess the effectiveness of a treatment in routine, every-
day practice; on the other side explanatory trials are
those designed to assess the efficacy of a treatment (usu-
ally compared with placebo) under ideal, experimentalconditions [13]. Pragmatic trials and the ITT approach
are naturally connected as the last one focuses on the
treatment allocated and not on what and/or how the
treatment was really taken, which is precisely what typ-
ically occurs in routine, everyday practice. However, the
standard application of the ITT approach is possible
only when complete outcome data are available for all
randomized subjects, and it requires explicit description
of the handling of deviations from randomized alloca-
tion and missing responses [14].
Problems caused by intermediate outcomes
The intention-to-treat (ITT) effect is not a causal effect; it
is the effect of being randomized to the experimental (or
active) treatment in comparison to the control treatment
[15]. On some occasions IOs make this ITT effect irrele-
vant, or at least secondary. For example, due to noncom-
pliance the effect of being assigned the experimental
treatment and actually receiving it can be very different,
and we might be interested mostly (or also) in the last one
(the causal effect). In other cases, the final outcome is not
defined for certain values/categories of the IO, and the
ITT effect is useless; for example in our calcium trial the
final outcome, preeclampsia, is not defined for women
who do not get pregnant, and the ITT would force the
analysis to consider preeclampsia in non-pregnant women
as zero (or some other unjustified and surely inappropriate
value). It should be noted also that using regression
models to adjust for IOs is not the solution, mainly
because this approach forces us to base the decision to
treat (with the experimental treatment) on information
not available at the required time (which is emulated
within a RCT by the time when randomization is made).
Within the context of an RCT, the ITT is (almost)
always unbiased, while the effect derived from the
as-treated analysis (where subjects are grouped and
compared according to the treatment actually received)
is generally biased; the ITT effect estimates the effect of
being randomized to the experimental treatment, while
the as-treated effect estimates the effect of actually re-
ceiving the experimental treatment. So if we are inter-
ested in the causal effect it could be argued that,
ultimately, it might be better to have a biased answer to
the right question than a perfect answer to the wrong
question. Fortunately, due to appropriate statistical
techniques, we can have a close-to-unbiased answer to
the question about the relevant causal effect.
As in many other research areas, noncompliance and
missing data are two rather common IOs in reproductive
health research RCTs. For example in a recent Cochrane
Review of calcium supplementation during pregnancy for
preventing hypertensive disorders and related problems
[16], four out of thirteen trials included in the review had
significant noncompliance (15% or more), and five out of
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noncompliance, three trials [17-19] approached this prob-
lem using (modified versions of) ITT, and in one trial [20]
it was approached using sensitivity analysis.
It is also frequent to have IOs generating so-called
truncation by death (or partially defined final outcomes
[21]) as in the case of the calcium trial, where the final
outcome preeclampsia is not defined if the woman does
not get pregnant. It should be noted that noncompli-
ance is an IO that does not prevent us from observing
the final outcome, while missing data does (although in
this last case the missing outcomes are potentially ob-
servable and can eventually be imputed); this illustrates
very clearly that there are relevant differences between
various IOs.
Principal stratification and instrumental variables for
intermediate outcomes
PS is a conceptual framework developed in the setting
of counterfactual causal inference to deal with situations
where the causal path from the treatment to the out-
come includes an IO variable that cannot be ignored
[5]. PS can be viewed as having its seeds in the IV
method, which originated in non-experimental econo-
metric studies a long time ago; under the PS approach
the IV method has been re-interpreted as a way to
approach a randomized experiment that suffers from
IOs [22].
Our presentation in these sections borrows, among
others, from Stuart et al. [15] and Yau and Little [23].
Stuart et al. [15] make a comprehensive non-technical
presentation of PS and IV in the context of noncompli-
ance as an IO, and the paper by Yau and Little [23]
describes how to account for more than one IO in the
same trial, specifically noncompliance and missing data.
Let us consider a general situation where each member
i of a set of N subjects has been randomly assigned to
either an experimental treatment (Ti = 1) or a control
treatment (Ti = 0). If there are k ordered intermediate
outcomes IO1, IO2, . . ., IOk, and all of them are binary
(IOj = 1 or 0 for all j), we will denote by:
Pi ¼ IO1i; IO2i; . . . ; IOkið Þ
the k-dimension vector with the observed profile for
subject i, out of 2k possible profiles. If the k intermedi-
ate outcomes are not ordered then there is a possible
maximum total of 2k × k! profiles. For example in our
calcium trial the IOs, pregnancy, and missing, are in
general not ordered in the sense that they can occur in
different sequences (missin,g either before pregnancy or
after pregnancy); accounting for this complication
means that there would be a total of 22 × 2! = 8 profiles.Finally let us assume that each subject has two poten-
tial (final) outcomes: Yi (Ti = 1, Pi), the outcome we
would observe if subject i is assigned to the treatment
group and has profile Pi, and Yi (Ti = 0, Pi), the outcome
we would observe if subject i, is assigned to the control
group and has profile Pi; it should be noted however
that for subjects in some profiles the Yi outcome might
not be (sufficiently) defined due to the interference of
IOs generating truncation by death or partially defined
final outcomes [21].
The ITT effect of the treatment for subject, i, is defined
as the difference in subject i’s outcomes if assigned to
experimental versus control treatment:
τi ¼ Yi Ti ¼ 1; Pið Þ–Yi Ti ¼ 0;Pið Þ
For each subject, however, we are able to observe
only one of these two potential outcomes. Some au-
thors consider potential outcomes and counterfactuals
as exchangeable, but as pointed about by Rubin [24], it
is safer to keep a distinction in the sense that after
assignment (and a particular profile of IOs) one of the
potential outcomes is observed while the other turns a
counterfactual, while before assignment they were not
counterfactuals.
For subjects in the experimental group we observe Yi
(Ti =1, Pi) whereas for subjects in the control group we
observe Yi (Ti = 0, Pi). We can, however, estimate the
overall average treatment effect (the ITT effect), which
is a comparison of outcomes if everyone was assigned to






Yi Ti ¼ 1; Pið Þ  Yi Ti ¼ 0; Pið Þ ð2Þ
Given our previous assumption of binary treatment
assignment, and the k binary and ordered IOs, there are
then 2 × 2k = 2k+1 profiles that can be properly com-
bined to form (principal) strata; each stratum is created
to group together subjects with a particular profile Pi
both under treatment and under control (Ti =1 and
Ti = 0, respectively), so in general there will be also 2k+1
principal strata. For example in the calcium trial the
possible (ordered) IOs compliance, pregnancy, and
missing, would generate 23+1 = 16 principal strata as a
result of considering the eight profiles from IOs under
the two possible assignments (to treatment and
control).
Therefore, we can also express the overall ITT effect
as the (weighted) average of the ITT effects for each of
these 2k+1 strata, that is:
τ ¼ p1τ1 þ p2τ2 þ . . .þ p2kþ1τ2kþ1 ; ð3Þ
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and τj the corresponding average treatment assignment
effect.
Two important properties of this stratification using
potential outcomes, known as PS, are: i) it stratifies on
the indicators of the IOs (observed at randomization
and not affected by it), but not on the observed IOs,
which are outcomes generally affected by the treatment
received [25], and ii) we might find that at least for one
of these strata, the effect of assignment to the experi-
mental treatment (the ITT effect) is (almost) the same
as the relevant causal effect.
For example, in the calcium trial and considering the
three ordered IOs (compliance, pregnancy, and missing),
property ii) above is illustrated by considering the spe-
cific stratum non-missing, always pregnant, and com-
pliers; the ITT effect for this principal stratum is (close
to) what we could call the causal effect of calcium on
preeclampsia.
In the next sections we will describe PS and IV in the
context of two frequent IOs in reproductive health re-
search, namely, noncompliance and pregnancy. Section
“Compliance as intermediate outcome” presents the PS
approach, and the Sections “Assumptions underlying
CACE analyses”, “Simple description of estimation” and
“More complex estimation” describe the simple version
of the IV technique within the specific context of non-
compliance as the only IO. We also discuss the specific
characteristics of the truncation by death (or partially
defined) type of IO, and why the simple IV estimate
presented in Section “Compliance as intermediate out-
come” might not be applicable [25].Compliance as intermediate outcome
As before, let us consider that each member of a set of
n subjects has been randomly assigned to either an
experimental treatment (Ti = 1) or a control treatment
(Ti = 0), and let us assume some of the experimental
group members actually receive the control treatment,
and some of the control group members may actually
receive the experimental treatment. Denote the actual
treatment received (the only IO in this case) as Pi (that
is, now having only 21 = 2 profiles). As before let us con-
sider the situation where the treatment (assigned or re-
ceived) is either 0 or 1, indicating control treatment or
experimental treatment. Each subject has two potential
outcomes: Yi (Ti =1, Pi), the outcome we would observe
if subject i is assigned to the treatment group, and Yi
(Ti = 0, Pi), the outcome we would observe if subject i is
assigned to the control group. As before, the ITT effect
of the treatment for subject i is defined as:






Yi Ti ¼ 1; Pið Þ  Yi Ti ¼ 0; Pið Þ:
Given our assumption of binary treatment assignment
and intake, there are now four types of subjects (strata),
defined by their compliance behavior when assigned to
the experimental treatment and their compliance behavior
when assigned to the control treatment. These four strata
[26] are:
1 Compliers (C), who fully take the experimental
treatment when assigned to it, and fully take the
control treatment when assigned to it: (Ti, Pi) =
(1, 1) and (Ti, Pi) = (0, 0); for example, in a standard
clinical trial of a new drug versus placebo, these are
the patients who would take the drug if in the
treatment group but not if they are in the control
group.
2 Always-takers (AT), who fully receive the
experimental treatment when in either the
experimental or control group: (Ti, Pi) = (1, 1) and
(Ti, Pi) = (0, 1); for example, patients who would
take the drug if they are in the treatment group, and
would also be able to take it if they are in the
control group.
3 Never-takers (NT), who do not receive the
experimental treatment when in either the
experimental or control group: (Ti, Pi) = (1, 0) and
(Ti, Pi) = (0, 0); for example, patients who would not
take the drug if in either the treatment or control
groups.
4 Defiers (D), who do not take the experimental
treatment when in the experimental group, but do
take the experimental treatment when in the control
group: (Ti, Pi) = (1, 0) and (Ti, Pi) = (0, 1); for
example, patients who would not take the drug if in
the treatment group, but would take the drug if in
the control group.
Therefore, we can also express the overall ITT effect
as the (weighted) average of the ITT effects for each of
these four types, that is:
τ ¼ pCτC þ pATτAT þ pNTτNT þ pDτD; ð4Þ
where pj is the proportion of the population in stratum j
and τj is the corresponding average treatment assign-
ment effect.
The second of the two main properties mentioned in
the previous sections means in this case that for the
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treatment condition, the effect of assignment to the ex-
perimental treatment (the ITT effect) is the same as the
effect of (fully) receiving it (the causal effect). Thus, our
interest is in the overall ITT effect as well as the effect of
assignment for the compliers stratum, or compliers aver-
age causal effect (CACE).Assumptions underlying CACE analyses
The effect of being randomized to treatment or to control
can be easily obtained comparing the average outcomes of
patients in the randomized treatment and control groups.
The problem in estimating the CACE is essentially a result
of the inability to identify which subjects belong to each of
the four principal strata defined in the previous section.
For example, patients randomized to the control group
who do not take the treatment can be either compliers or
never-takers, and those who do take the treatment can be
either always-takers or defiers; a similar unidentifiability
problem occurs with those randomized to the treatment
group.
If we could observe the compliance behavior of subjects
when simultaneously assigned to treatment and to control
we would be able to address the unidentifiability problem,
but we never can observe this. The standard IV approach
imposes a basic set of assumptions to help us estimate the
CACE effect. Those assumptions are [15]:
1 The outcomes of each individual are not affected by
the treatment assignments of any other individuals.
This assumption is made in nearly all studies
estimating causal effects, and is known as no
interference, or the stable unit treatment value
assumption (SUTVA) [27]).
2 Being given the opportunity to take the treatment
was assigned randomly.
3 Being given the opportunity to take the treatment
induces some individuals to actually take it. In
other words, there are some compliers. This is
sometimes labeled as the non-zero denominator
assumption.
4 There are no defiers. This is sometimes called
monotonicity, to reflect the assumption that
being told (encouraged) to do something (taking
active treatment or placebo) cannot make you to
do the opposite. This assumption helps identify
the compliers by ruling out particular behaviors.
5 There is no effect of assignment for the never-takers
or for the always-takers. In other words, since being
assigned to the treatment group versus the control
group does not change the patient’s treatment-taking
behavior, neither change their outcomes. These
assumptions (one for the always-takers and one forthe never-takers) are known as the exclusion
restrictions.
Simple description of estimation
Following [15], we will describe how the above assump-
tions can help us estimate the CACE. We are mainly
interested in estimating τC, the effect for compliers, as
expressed in formula (3). First, the no defiers assumption
(assumption 4) implies that pD = 0; and second, the exclu-
sion restrictions (assumption 5) imply that τAT = τNT = 0.
This means that ITT = τ = pCτC. So, under the above
assumptions, if we can estimate pC we can obtain an
estimate of τC, the effect of interest.
To estimate the proportion of compliers, pC, we con-
sider the patients in the treatment group who fully partici-
pate, who could then be either compliers or always-takers.
Since we have assumed that there are no defiers (assump-
tion 4), patients in the control group who fully take the
treatment (fully participate) must be always-takers; there-
fore we can estimate the percentage of always-takers, pAT,
as the proportion of patients in the control group who
(fully) take the treatment.
Under assumption 2 (random assignment) the pro-
portion of always-takers should be the same in the
treatment and control groups (idem for the compliers
stratum). This means that pAT can be estimated from
the control group, and pC + pAT can be estimated from
the treatment group; this allows us to estimate the
proportion of compliers pC, and finally the CACE from
τC = ITT/pC = τ/pC.
More complex estimation
When the previously listed assumptions are implaus-
ible, identification of the PS requires new and more
complicated assumptions, and/or methods involving
relevant covariates [15,25]. The IV approach in this
case involves a TSLS regression, which jointly models
the two processes of treatment received (IO) and the
Y outcome observed [10,15]. Within the IV approach,
one model in TSLS predicts treatment received R
(the IO), given treatment assigned T, and a second
model predicts outcome observed Y, given treatment
received R (the IO). Both models are estimated jointly,
to calculate accurate standard errors that account for
the uncertainty in the first-stage model [15]. The TSLS
allows the inclusion of covariates that predict treat-
ment received R, and/or the outcome Y, which should
increase the precision of the estimates [15]. Within
this context it is possible to see that the term instru-
ment represents the randomization to the treatment
or control group (treatment assigned, T), which is as-
sumed to influence treatment received, R (the IO) but
not the outcome observed, Y (except through its effect
on the IO treatment received); that is, the treatment
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model of the IO (R) but not in the model of the final
outcome Y [15]. The specific models [15] are:
Yi ¼ β0 þ β1Ri þ θXi þ ei
Ri ¼ α0 þ α1Ti þ φWi þ vi ð5Þ
where Yi is the final outcome of interest, Ti is treatment
assigned, IOi is treatment received (IO), the matrix X rep-
resents covariates that predict the outcome Y, and W con-
sists of covariates that predict treatment received R (there
may be overlap between the predictors in X and W). In the
first model for Yi in [4] we do not use the observed IOi but
the predicted IOi from the second model, which reduces
the endogeneity of IOi and improves the prediction of Yi.
An intuitive rationale for the TSLS method in these
contexts was given previously (formula (1)). Alternative
estimation approaches include maximum likelihood [27]
and Bayesian methods [28]. The TSLS technique is avail-
able in all main statistical packages.
Truncation by death intermediate outcomes
The general approach considered under Section “Compli-
ance as intermediate outcome” applies to truncation by
death IOs. Now IOi denotes if subject i does or does not
have the intermediate outcome, such that IOi (Ti =1)
reflects the status of the IO in subject i if assigned to
the experimental group and IOi (Ti =0) reflects the
status of the IO in subject i if assigned to control. In this
section we will assume that lack of compliance is not a
problem in the trial.
The same labels for the four principal strata can be
used, as (without loss of generalization), for example,
compliers are considered as those who have the good IO
when assigned to treatment and do not have it when
assigned to control [25]. However, some of the key as-
sumptions made in the case of noncompliance are usu-
ally not plausible in the case of truncation by death IOs.
For example the monotonicity or no defiers assumption
(assumption 4) could be controversial, as we could not
rule out the existence of subjects not having the (good)
IO when treated, while having it when not treated [25].
Furthermore, the exclusion assumption (assumption 5)
is in general not sustainable, as it states that assignment
to the (active) treatment does not have any effect on the
stratum, always with the IO present (the AT stratum as
previously described), and the stratum, always with the
IO absent (the NT stratum). But if the final outcome Y
is defined only when the IO is present, then the effect of
assignment on Y in the AT stratum is precisely what we
are interested in, so we cannot assume that the effect on
this stratum is zero [25].
As previously noted, when all the five previously stated
assumptions hold, the IV estimate is the simple treatmentminus control estimate for the mean of Y divided by the
simple treatment minus control estimate for the mean of
intermediate outcome R (from formula (2)). So, even if we
were able to accept all these assumptions when dealing
with a truncation by death IO, we would require some im-
putation of the missing Y values for those subjects where Y
is in fact not defined. As expected this arbitrary imputation
usually results in arbitrarily distorted results [25]. We can
then observe that in the case of truncation by death IOs,
the simple estimation described in Section “Simple descrip-
tion of estimation” is in general not applicable, and add-
itional or different assumptions should be made to be able
to make a simple estimation. Alternatively more complex
estimation approaches using covariates (as described in
Section “More complex estimation”) must be used. Unfor-
tunately, software for implementing PS are not readily avail-
able. A reference to one such program in R, PSpack, was
made in 2004 [29] but we have not been able to locate it.
Results
Application to the calcium trial
Section “Noncompliance as intermediate outcome” will
present the application of the methods described in Sec-
tions “Compliance as intermediate outcome”, “Assumptions
underlying CACE analyses” and “Simple description of esti-
mation” to the particular scenario of our calcium trial,
where noncompliance is considered as an IO between cal-
cium assignment and pregnancy as the (final) outcome.
Section “Pregnancy as a “truncation by death” intermediate
outcome” will illustrate the need for approaches beyond the
standard PS approach (for example, IV) in the case of preg-
nancy as a truncation by death IO between calcium assign-
ment and preeclampsia. Finally Section “Noncompliance
and pregnancy as intermediate outcomes” will discuss how
to account for both noncompliance and pregnancy as IOs
in our calcium trial.
Noncompliance as an intermediate outcome
From Tables 1 and 2 we see that if a subject is assigned
to calcium and takes calcium, she can be a complier (C)
or an always-taker (AT). If she is assigned to calcium
and does not take calcium then she has to be a never
taker (NT), as it is not possible to have defiers in our
trial (D =Ø); the difference between never-takers and
defiers might be slim, but it is essentially determined by
the fact that our study is double-blinded, so subjects are
told to do the same thing in both arms, that is, to take
the pills assigned.
If a subject is assigned to placebo and takes placebo,
she can be a complier (C) or a never-taker (NT); if she
is assigned to placebo and takes calcium she has to be
an always-taker (AT) as there are no defiers (D =Ø).
Then from what we observe in the calcium arm we have
estimations of pC+AT and pNT, and from the placebo arm
Table 1 Principal strata and sources of (non)compliance





























Compliers Yes No No Yes No No
Yes Yes No Yes Yes No
Yes Yes Yes Yes Yes Yes
Always- takers Yes No Yes Yes No Yes
No Yes No No Yes No
No Yes Yes No Yes Yes
No No Yes No No Yes
Never-takers No No No No No No
Defiers*
*As the trial is blinded, there are no defiers, as subjects cannot systematically take the opposite treatment. If a subject decides not to take the pills (treatment)
assigned, she belongs to the never-takers stratum. Compliers are subjects who always take the treatment assigned.
aSources of (non)compliance: 1, taking >80% of pills assigned; 2, collateral treatment involving substantial calcium indicated by physician; 3, self-indicated
collateral treatment involving substantial calcium.
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we get two estimations for pC,
p^C1 ¼ p^CþAT  p^AT
p^C2 ¼ p^CþNT  p^NT
ð6Þ
and their (weighted) average pC can be used as an
estimation of the proportion of compliers in the
population.
Assumption 1 (SUTVA) is sustained in our trial because
the risk of pregnancy in woman i is not affected by theTable 2 Principal strata according to potential behavior
in each source of noncompliance (alternative version of
Table 1)
Strata Behavior pattern in
noncompliance sources
1, 2 and 3a
Treatment assigned and
received for subject R in
corresponding stratum











No, no, no Ri(Ti) = 0
Defiers*
*As the trial is blinded, there are no defiers, as subjects cannot systematically take
the opposite treatment; **Ri = treatment received, Ti = treatment assigned (0=
placebo, 1 = calcium); asources of (non)compliance: 1, taking >80% of pills
assigned; 2, collateral treatment involving substantial calcium indicated by
physician; 3, self-indicated collateral treatment involving substantial calcium.treatment received by women j, for all j ≠ i; as the treatment
is administered at the level of the individual woman and
the trial is double-blinded, there is nothing a particular
woman or her physician can do to modify her outcome,
from what they observe in other women in the trial. This
assumption is required to be able to define an effect at the
individual-woman level, which is implicit in the definition
of the CACE.
Assumption 2 is sustained as the calcium trial is an
RCT. Assumption 3 is sustained as we expect in fact that
most of the subjects in both arms will comply. Assump-
tion 4 (monotonicity) is sustained because as already
discussed, the double-blinded design of the study prevents
women from consistently taking the opposite treatment to
the one assigned, so D =Ø. And finally assumption 5 (the
exclusion restrictions) is sustained because the risk of
pregnancy in our trial depends on calcium intake, not on
calcium assignment; that is, given IOi, the risk of preg-
nancy is independent of Ti, and therefore, there is no ef-
fect of assignment on pregnancy for those who always
behave the same (AT and NT strata).
Therefore, our calcium CACE can be estimated from
the ITT effect and the estimated proportion of women




Pregnancy as a truncation by death intermediate
outcome
In the calcium trial if compliance is (almost) perfect (for
example, if for >95% of subjects i, IOi =Ti), we can
Table 3 Covariates for the two-stage least squares
(TSLS) analysis
Regression model for pregnancy, given treatment assignment:
Questions on the form: Description of the covariate:
ADM_Q2 Age (years)
ADM_Q3 Parity (previous pregnancies >24 weeks)
ADM_Q14 Any health problems
ADM_Q1SA Blood pressure systolic (normal/abnormal)
ADM_Q15B Blood pressure diastolic (normal/abnormal)
ADM_Q16 Body mass index (normal/abnormal)
ADM_Q17
Regression model for preeclampsia. Given pregnancy:
Questions on the form: Description of the covariate:
ADM_Q2 Age (years)
ADM_Q3 Parity (previous pregnancies >24 weeks)
ADM_Q14 Any health problems
ADM_Q1SA Blood pressure systolic (normal/abnormal)
ADM_Q1SB Blood pressure diastolic (normal/abnormal)
ADM_Q16 Body mass index (normal/abnormal)
ADM_Q17
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eclampsia accounting for pregnancy as the only IO; and
pregnancy is an IO which generates truncation by death,
as the final outcome Y, preeclampsia is defined only for
pregnant women (that is, when the IO is present).
As mentioned before, we do not expect calcium to influ-
ence the risk of pregnancy, but if we unfortunately observe
a significant effect, we will have to consider pregnancy as
an IO and account for it properly. In this case we will label
the relevant causal effect as pregnancy average causal effect,
or PACE, as we are only interested in the possible effect of
assignment to calcium on preeclampsia among women
who get pregnant within the trial (the AT stratum), now
better labeled as the always-pregnant stratum).
Some of the assumptions made in Section “Assumptions
underlying CACE analyses” to estimate the CACE (as in
Section “Noncompliance as intermediate outcome”) are
now inappropriate, and some new assumptions are rele-
vant and possibly convenient. For example we have just
seen that assumption 5 (the exclusion-restriction assump-
tions) is generally unsustainable, because we are usually
interested in the effect on those who have always the IO
present (that is, the AT or always-pregnant stratum),
which then cannot be assumed to be zero. On the other
hand, additional assumptions now make sense. For ex-
ample in our trial calcium could either increase or de-
crease the risk of pregnancy, but not both; if calcium does
decrease the risk of pregnancy (which might be the case if
there is any effect at all), then we might question the com-
pliers stratum, that is, we could assume that there are no
women who get pregnant under calcium or under pla-
cebo. We will subsequently consider this in more detail,
where the two IOs, compliance and pregnancy, will be
combined and a simple estimate will be pursued. One of
the main reasons for the differential sustainability of the
set of assumptions between compliance and pregnancy as
IOs is that compliance is an IO quite connected to the be-
havior of individuals, and to some extent under their sub-
jective control, while pregnancy is not. In other words,
(lack of) compliance can be heavily addressed using social
sciences tools, while (lack of) pregnancy cannot.
If revising and making additional assumptions do not
make the simple estimate feasible we can alternatively use
the TSLS technique as previously described to address the
problem of pregnancy as an IO. The relevant issue in this
case would be then to identify relevant covariates for the
model of R (IO pregnancy) given T (treatment assigned),
and for the model of outcome Y (preeclampsia) given R,
that is, matrix W and X respectively (see expression (4) in
Section “More complex estimation”). From the baseline
form of our calcium trial we identified several potential
good predictors of pregnancy and of preeclampsia, which
are presented in Table 3 and will eventually be used in the
TSLS analysis.Noncompliance and pregnancy as intermediate outcomes
When we combine compliance and pregnancy as IOs
between calcium assignment and preeclampsia we get
16 principal strata as a result of combining the four
principal strata of noncompliance with the corre-
sponding four of pregnancy (see Table 4). The insertion
of pregnancy as a truncation by death IO means that
the (average treatment assignment) effects in many of
the strata are not defined (12 out of 16), as the effect of
calcium assignment on preeclampsia is defined only
for strata where women get pregnant under both arms
of the trial (always-pregnant strata 7, 12, 14 and 16). In
fact within these four strata where the effect is defined,
in two (strata 7 and 16) the effect is zero because of the
exclusion restrictions assumption (assumption 5, Section
“Assumptions underlying CACE analyses”); and finally the
effect for stratum 14 does not influence the global
ITT effect, as this stratum is empty (no defiers or
monotonicity assumption 4, Section “Assumptions
underlying CACE analyses”). Therefore the global ITT






Yi Ti ¼ 1; Pið Þ  Yi Ti ¼ 0; Pið Þ:
¼ p1τ1 þ p2τ2 þ . . .þ p16τ16
¼ p7τ7 þ p12τ12 þ p14τ14 þ p16τ16
¼ p12τ12:
ð8Þ
Then to solve for τ12 in [8] we only need to have an
estimate of p12.
Table 4 Principal strata for both compliance and pregnancy as IOs
Treatment assigned
























1 0 0 0 0 Never-takers
never pregnant
* * p1 *
2 0 0 0 1 Never-takers
pregnant under
treatment
* (no, yes) p2 *
3 0 0 1 0 Compliers
never-pregnant
* * p3 *
4 0 1 0 0 Never-takers
pregnant under
control
(no, yes) * p4 *
5 1 0 0 0 Defiers
never-pregnant
* * 0 *
6 0 0 1 1 Compliers
pregnant under
treatment
* (no, yes) p6 *
7 0 1 0 1 Never-takers
always-pregnant
(no, yes) (no, yes) p7 0
8 1 0 0 1 Defiers pregnant
under treatment
* (no, yes) 0 *
9 0 1 1 0 Compliers
pregnant under
control
(no, yes) * p9 *
10 1 0 1 0 Always-takers
never-pregnant
* * p10 *
11 1 1 0 0 Defiers pregnant
under control
(no, yes) * 0 *
12 0 1 1 1 Compliers
always-pregnant
(no, yes) (no, yes) p12 τ12
13 1 0 1 1 Always-takers
pregnant under
treatment
* (no, yes) p13 *
14 1 1 0 1 Defiers
always-pregnant
(no, yes) (no, yes) 0 τ14
15 1 1 1 0 Always-takers
pregnant under
control
(no, yes) * p15 *
16 1 1 1 1 Always-takers
always-pregnant
(no, yes) (no, yes) p16 0
*Final outcome or effect not defined; **it is possible in theory to have always-takers, because women can take calcium supplementation out of the trial intervention.
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in our calcium trial and the corresponding principal strata
behind them (from Table 4), which clearly illustrates the
identification problem. Under the current assumptions we
see that the stratum we want to identify (stratum 12) is
linked to other three (nuisance) strata both in the OBS
(111) group (women randomized to calcium, receiving
calcium, and pregnant) and in the OBS (011) group
(women randomized to placebo, receiving calcium,
and pregnant).
It is then obvious that we need to make reasonable
additional assumptions if we want to obtain a simpleestimate of the causal effect of calcium on preeclampsia.
First, it might make sense to additionally assume that
a) the never-takers (NT) stratum is empty, as women
recruited into the trial are not mentally sick, and
will be properly informed about the potential
advantages and disadvantages of calcium
supplementation; in this scenario to have never-
takers could be considered close to impossible. This
new reasonable assumption quite simplifies the
identification process, as now strata 1, 2, 4 and 7 are
all empty (that is, p1 = p2 = p4 = p7 = 0 ).We can also
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the possible effect of calcium on pregnancy. Calcium
intake can affect pregnancy either by increasing or
by decreasing its risk, and we could (additionally)
assume that if any,
b) calcium increases the risk (probability) of pregnancy.
This means that the compliers stratum with women
getting pregnant with placebo and not with calcium
(stratum 9 in Table 4) is empty (that is, p9 = 0).
These additional assumptions a) and b) allow us to
identify the number of subjects in stratum 12 from
the number of subjects observed in OBS(001), so we
can estimate p12 and then τ12 from (7).
Complementary assumptions, a1) and a2):a) a1) the always-takers (AT) stratum is empty, and
b) b1) calcium decreases the risk (probability) of
pregnancy,
could be made, which would also allows us to identify (the
number of subjects in) stratum 12 from the number of
subjects in OBS(111), and then estimating p12 and finally
τ12 from (7). Assuming a1) in addition to a) is plausible,
but obviously b1) and b) exclude each other.Discussion
In this paper we have presented an introduction to the
PS approach and how it can be applied to account for
IOs in RCTs. Some other papers have further discussed
its assumptions and limitations, as well as alternative
approaches [15,23]. Here we would instead like to focus
on why we really need to move beyond the (modified)
ITT approach when dealing with IOs, and to debate on
some of the obstacles possibly blocking the way out.Table 5 Observed groups (according to treatment assigned re
principal strata
Description Principal strata under i
Randomized to calcium:
OBS(100) received placebo and non pregnant 1, 4
OBS(101) received placebo and pregnant 2, 7
OBS(110) received placebo and non pregnant 3, 9, 10,
OBS(111) received placebo and pregnant 6, 12, 13
Randomized to Placebo:
OBS(000) received placebo and non pregnant 1, 2, 3,
OBS(001) received placebo and pregnant 4, 7, 9,
OBS(010) received placebo and non pregnant 10, 13
OBS(011) received placebo and pregnant 15, 16
OBS (ijk), observed women randomized to i (0 = placebo, 1 = calcium), receiving j (0
are assumptions 1 to 5 in Section “Noncompliance as intermediate outcome”; **add
pregnancy as intermediate outcomes”.
NA, the corresponding principal strata are empty under additional assumptions.First of all, there is an increasing trend to label trials as
pragmatic under the assumption that they are more rele-
vant to public health decision makers (PHDM); this usually
comes together with the attractive statement that in prag-
matic trials a comprehensive and consistent ITT approach
is just what is needed. It would seem then that the resulting
combined package is unbeatable. However, some pragmatic
trials are really hybrid, and then imply an interest in know-
ing why the experimental intervention does (or does not)
work, as this information could be required by PHDM
when implementing trial results in different contexts (in
fact the causal effect is considered by some as more
generalizable than the ITT effect [15]. This means that on
some occasions pragmatic trials include an explanatory
component related to the causal effect of the intervention
tested (considered complex but relevant [14,30]), or related
to effects estimated on other subgroups of patients defined
by alternative IOs (for example, women with complete fol-
low up, women who got pregnant during the trial, et
cetera). And this means that on occasions the ITTapproach
is not the answer for all the relevant questions.
The CONSORT 2010 guidelines [31] widely recommend
the use of the ITT approach but do not make explicit men-
tion of IOs; two particular cases of IOs, noncompliance and
missing data, are mentioned but no details are given on
how to address them, which is expected as these guidelines
attempt to give advice on the reporting of what was done
and not to judge on particular methods. In the case of non-
compliance the CONSORT guidelines say: ‘Noncompliance
with assigned therapy may mean that the intention-to-treat
analysis underestimates the potential benefit of the treat-
ment, and additional analyses, such as a per protocol ana-
lysis, may therefore be considered. It should be noted,
however, that such analyses are often considerably
flawed.’ In the case of missing data CONSORT saysceived and pregnancy status) and corresponding
nitial assumptions* Principal strata under additional assumption**
NA
NA
15 3, 9, 10, 15





= placebo, 1 = calcium), and pregnant k (0 = no, 1 = yes). *Initial assumptions
itional assumptions a) and b) described in Section “Noncompliance and
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in the analysis only if their outcomes are imputed’; in fact,
consequent application of the ITT approach requires im-
putation of missing data.
Some researchers conclude from the above CONSORT
recommendations that the ITT approach can properly
account for IOs, as alternative approaches are rather ob-
scure or dubious. In fact, one of the unintended prob-
lems of the ITT approach is that in some contexts it has
allowed counterproductive and excessive relaxation to
flourish. Labeling a trial as having an ITT approach is
seen by some as a quality guarantee or safe haven, which
has been proved not to be the case at all [14]. Some re-
searchers also believe that the ITT approach is univer-
sally applicable, not noting that full application of the
ITT approach is possible only when complete outcome
data are available for all randomized subjects [14], this
being relevant both for lost to follow up data and for
truncation by death IOs. Some suggestions have been
presented to minimize losses to follow up and the corre-
sponding negative impact of missing data [30] but they
do not apply to truncation by death IOs, and to some
extent are not in the spirit of pragmatic trials.
Unfortunately it has become common practice to con-
sider that pragmatic trials (and the corresponding ITT
approach), can emphasize on wide generalizability at the
expense of methodological rigor, but this ‘. . .can result
in invalid and unreliable results. Achieving a creative
tension between the two is crucial’ [32]. Particularly in
relation to treatment compliance, it ‘. . .is one of the
most important outcomes of pragmatic trials. Unlike ex-
planatory trials where compliance with the intervention
must be ensured in order to know that the intervention
can work, in pragmatic trials compliance with the inter-
vention is measured as an outcome’; and: ‘Compliance is
not something you necessarily struggle to maintain but
rather something you measure as an outcome. Lack of
compliance in the “real world” frequently renders an
efficacious intervention ineffective’ [33].
Conclusions
We hope that this paper and discussion will help re-
searchers to be critical about the limitations of the ITT
approach to account properly for the quite common
presence of IOs in RCTs, and that possibly more com-
plex but definitely more appropriate approaches be bet-
ter known and eventually applied. The sound basis of
the ITT approach is widely appreciated, but we should
also recognize that it does not fit all problems and that
on occasions, as illustrated in this paper it should be
complemented by alternative approaches.
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